Marathon Pharmaceuticals Names Joe Nolan Chief Commercial Officer

CHICAGO--(BUSINESS WIRE)--Marathon Pharmaceuticals, LLC, a biopharmaceutical company focused on developing treatments for rare diseases and neurological disorders, today announced that Joe Nolan has joined the company as chief commercial officer. In his new role, Mr. Nolan will oversee the commercial development, marketing and launch of Marathon's rare disease treatments.

"He will be key to the success of our upcoming rare disease product launches."
Mr. Nolan's experience in the pharmaceutical industry spans nearly three decades. Prior to joining Marathon's executive team, Mr. Nolan spent 18 years leading marketing and business development efforts for multi-billion-dollar pharmaceutical companies including Lundbeck, Takeda and Abbott, as well as 10 years working to build startups into mid-size pharmaceutical companies.

During his tenure at Lundbeck, Mr. Nolan led the company's global licensing and business development, third-party alliances, new product development, product launches and strategic business planning in the United States, including the recent acquisition and integration of Chelsea Therapeutics into the Lundbeck portfolio.

Mr. Nolan earned his Master of Business Administration degree from the University of Notre Dame and a bachelor's degree in marketing and finance from Tulane University. He has served on the board of directors for Illinois Biotechnology Industry Organization (iBIO) and the Illinois Science and Mathematics Academy (ISMA).

"Joe is a proven industry leader who can help Marathon continue to grow and deliver new rare disease treatments to the patients who need them," said Jeff Aronin, CEO of Marathon. "He will be key to the success of our upcoming rare disease product launches."

Marathon Pharmaceuticals, LLC is a biopharmaceutical company that develops new treatments for rare diseases with a focus on providing medicine to patients who currently have no treatment options. The company is developing a pipeline of treatments for rare neurological and movement disorders. Marathon is headquartered in Northbrook, Illinois, with offices in Chicago, New Jersey and Washington D.C. For more information, visit www.marathonpharma.com.

Contacts

Aileron Communications
Peter Gray, 312.629.9400
[email protected]

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.

A month after seeing a "robust immune response" from a clutch of RSV vaccine hopefuls, GlaxoSmithKline is kicking off a key late-stage test.